CliffBio
small molecule

VARUBI

ROLAPITANT HYDROCHLORIDE

Loss of exclusivityOctober 2029latest FDA-listed patent expiry
CompanyTersera Therapeutics →View the full company profile on CliffBio

Drug detail

Brand nameVARUBI
Active ingredientROLAPITANT HYDROCHLORIDE
StrengthEQ 90MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2015
Marketing statusRX

Listed patents

PatentExpiresType
8361500October 2029product
8470842January 2029use U-1741
7049320August 2028substance, product
7981905April 2027use U-1741
7563801April 2027product
8404702April 2027use U-1741
8178550April 2027substance, product

More from Tersera Therapeutics

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VARUBI patent cliff — loss of exclusivity October 2029 | CliffBio